Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors

Commercially available antisera against five subtypes of muscarinic receptors and nine subtypes of adrenoceptors showed highly distinct immunohistochemical staining patterns in rat ureter and stomach. However, using the M 1–4 muscarinic receptor subtypes and α 2B -, β 2 -, and β 3 -adrenoceptors as...

Full description

Saved in:
Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology 2009-04, Vol.379 (4), p.397-402
Main Authors: Pradidarcheep, Wisuit, Stallen, Jan, Labruyère, Wil T., Dabhoiwala, Noshir F., Michel, Martin C., Lamers, Wouter H.
Format: Article
Language:English
Subjects:
Animals
Antibodies - immunology
Antibody Specificity - immunology
Biomedical and Life Sciences
Biomedicine
Blotting, Western
Brain Chemistry
Cell Line
Gastrointestinal Tract - chemistry
Humans
Immune Sera - immunology
Immunohistochemistry
Neurosciences
Pharmacology/Toxicology
Rats
Rats, Wistar
Receptors, Adrenergic - analysis
Receptors, Adrenergic - genetics
Receptors, Adrenergic - immunology
Receptors, Muscarinic - analysis
Receptors, Muscarinic - genetics
Receptors, Muscarinic - immunology
Special Article
Transfection
Urinary Tract - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Commercially available antisera against five subtypes of muscarinic receptors and nine subtypes of adrenoceptors showed highly distinct immunohistochemical staining patterns in rat ureter and stomach. However, using the M 1–4 muscarinic receptor subtypes and α 2B -, β 2 -, and β 3 -adrenoceptors as examples, Western blots with membranes prepared from cell lines stably expressing various subtypes of muscarinic receptors or adrenoceptors revealed that each of the antisera recognized a set of proteins that differed between the cell lines used but lacked specificity for the claimed target receptor. We propose that receptor antibodies need better validation before they can reliably be used.
ISSN:0028-1298
1432-1912
DOI:10.1007/s00210-009-0393-0